ArticleBMC veterinary research2026
Pilot evaluation of a liquid biopsy test for longitudinal monitoring of disease status in dogs undergoing treatment for multicentric lymphoma.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine lymphoma is a common malignancy with an annual incidence rate of 160 cases per 100,000 dogs. The primary therapeutic protocol in clinical use is treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); however, relapses remain frequent, and early detection of recurrence is challenging. IDEXX Cancer Dx™ testing is a commercially available, blood-based test developed for the detection of canine lymphoma and may also have utility as a minimally invasive tool for longitudinal monitoring during treatment. Ten client-owned dogs with cytologic confirmation of lymphoma, immunophenotyping by flow cytometry and/or genotypic clonality testing by PCR for antigen receptor rearrangement (PARR), and an initial response to CHOP therapy were enrolled in this prospective longitudinal study. Whole blood was collected serially during chemotherapy and analyzed using Cancer Dx testing, with results reported as positive or negative. Clinical response was evaluated using the Veterinary Cooperative Oncology Group (VCOG) response evaluation criteria for peripheral nodal lymphoma in dogs.
resultsCancer Dx test results showed concordance with clinical disease status (Somers' D = 0.70, 95% CI [0.59, 0.82]; Kendall's τ-b = 0.67, 95% CI [0.56, 0.78]). Among the ten cases, test results for eight (80%) dogs became negative, corresponding with clinical remission. Seven of ten (70%) dogs maintained negative test results during complete remission; five of ten (50%) dogs became positive at clinical relapse. Discordance between Cancer Dx testing results and clinical status at the time of initial clinical remission occurred in 2 out of 10 (20%) of the enrolled dogs. Two dogs (Dogs D and I) remained positive despite achieving clinical remission during the initial weeks of CHOP therapy, suggesting delayed or incomplete biomarker conversion.
conclusionSerial Cancer Dx testing results were concordant with VCOG Response Evaluation Criteria-defined clinical status. While these results support further investigation of Cancer Dx testing as a monitoring tool during chemotherapy for lymphoma, the current performance of the assay is insufficient for reliable, stand-alone monitoring without further refinement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.